Information and Supplementary
). The median size was 182.1 kb (166.3 kb for deletions, 194.4 kb for duplications), 39% were deletions and the median number per individual was 1. We assessed the impact of rare structural variation on the risk for schizophrenia in two ways: first in terms of an individual's genome-wide burden, and second by searching for specific loci that were significantly associated with disease.
Structural variants have been identified for severe neurodevelopmental disorders [9] [10] [11] 16, 17 . Because it has been postulated that schizophrenia might, at least in part, have a developmental aetiology 18 , we posited a role for CNVs in schizophrenia, as have others [2] [3] [4] [5] [6] . Several loci have been identified, including variants containing genes with neurodevelopmental roles [2] [3] [4] [5] . However, a critical question is the extent to which this is a general mechanism for producing schizophrenia in typical clinical populations rather than in cases selected for atypical phenotypic features such as very early onset or mental retardation. This motivated our primary hypothesis: that individuals with schizophrenia have a greater genome-wide burden of CNVs. Considering all CNVs, we observed that cases had a greater average burden than controls (one-sided, empirical P 5 3 3 10 25 controlling for array type; Table 2 ). Controls on average had 0.99 CNVs per person, whereas cases showed a 1.15-fold higher rate.
We next explored this subtle, but highly statistically significant, observation of increased burden. We defined burden in two ways: as the number of CNVs carried by an individual (as above), and also as the number of genes spanned by those CNVs. This second metric (the 'gene count') in fact showed a stronger association with schizophrenia (1.41-fold increase, empirical P 5 2 3 10
26
) than burden defined simply as the number of CNVs. Characteristics of CNV subgroups studied here are their frequency, type, size, and proximity to a gene (Tables 2 and 3, and Supplementary Table 2) . We observed an increased burden across multiple independent subgroups of CNVs, *Lists of members and affiliations appear at the end of the paper. a finding that was more pronounced for rarer CNVs and those involving genes. Deletions and duplications also had somewhat different profiles: the association of deletions varied more noticeably with respect to CNV size and proximity to a gene, whereas duplications showed a more uniform pattern.
A total of 890 CNVs were observed in either a case or a control as a single occurrence. This rarest subset of CNVs would be expected to show enrichment under the model that genetic causes of schizophrenia are individually unique in some proportion of patients. Indeed, this set of CNVs showed a 1.45-fold increase in cases (empirical P 5 5 3 10 26 ). On average, 13.1% of cases of schizophrenia possessed a deletion or duplication observed only once in the sample, in contrast to 10.4% of controls. Under a model in which very rare (occurring in under 1/1,000 individuals) inherited or recurrently de novo events increase risk, we would expect to observe a greater overall burden in schizophrenia. Although our study was statistically underpowered to identify the actual loci involved, such variants could in theory be mapped in extremely large samples. In this intermediate group, we observed 2,465 CNVs occurring between two and six times in the total sample, for which there was an increased burden, both for number of CNVs (empirical P 5 0.0013) and gene count (empirical P 5 5 3 10 24 ). Because several known genomic disorders of the nervous system result from large CNVs, which are often many hundreds of kilobases long 11 , we additionally stratified by size of event (Table 3) . Of deletions, only larger (more than 500 kb) variants were enriched (empirical P 5 3 3 10 24 ) despite being the least frequent set of CNVs (n 5 285), displaying a 3.57-fold increase in gene count between cases and controls (empirical P 5 2 3 10 25 ). In contrast, shorter duplications showed a stronger association with disease than longer duplications, albeit with a smaller fold increase than deletions (Table 3) .
In general, the gene count definition of CNV burden yielded stronger results, particularly for deletions (gene count P 5 3 3 10 25 versus number P 5 0.11; Table 2 ). In fact, dividing all CNVs into two sets, of those that intersect at least one gene and those that do not, we saw an increased burden only in the number of 'genic' CNVs (P 5 5 3 10 26 ; Supplementary Table 2) and not for non-genic CNVs (P 5 0.16). There was a similar trend for CNVs seen two to six times when comparing enrichment in genic and non-genic CNVs (P 5 7 3 10 24 and 0.19, respectively) but not single-occurrence CNVs (P 5 6 3 10 24 and 6 3 10 24 , respectively). These results may reflect biological distinctions, although they may to some extent also reflect variable performance in CNV detection for different classes of variant.
We conducted a set of analyses to rule out several sources of bias and confounding in the primary genome-wide burden analysis (Supplementary Tables 3-6 ). Although, in general, low specificity and sensitivity decrease power, of concern here is potential measurement error that varied systematically between cases and controls, leading to spurious results. In this respect, an obvious concern is that both Affymetrix 5.0 and 6.0 arrays were used; as a consequence, we performed all analyses controlling for array type. As described in Supplementary Information, the primary result was also robust to the following. First, in addition to array type, we controlled for sample collection site, genotyping plate and average probe variance. Second, sensitivity analyses showed that no single sample collection site accounted for the observations. Third, we restricted analysis to the most homogeneous 90% of the sample with respect to intraindividual probe variance. Fourth, if differences in CNV burden between cases and controls were purely due to unmeasured confounders, we would not expect an enriched gene count after controlling for the overall extent and rate of CNVs. However, after controlling for overall (genic and non-genic) CNV burden there remained a significantly enriched gene-count burden in patients with schizophrenia.
Our large sample size further enabled us to search for specific CNV regions associated with schizophrenia. One locus previously reported to increase risk for schizophrenia is 22q11.2 (17-21 megabases (Mb)), at which hemizygosity occurs in 1 in every 4,000 live births 12 . These deletions produce a range of clinically heterogeneous phenotypes, including velo-cardio-facial syndrome and DiGeorge syndrome, that The table shows an analysis of global CNV burden in cases versus controls. CNVs were stratified into three size categories (100-200 kb, 200-500 kb, and 500 kb or more). See Table 2 for further details.
together are known as 22q11.2 deletion syndrome (22q11.2DS) 12 ; about 30% of carriers develop psychosis 12 . Previous studies estimated the frequency of 22q11.2 deletions to be 0.6-2.0% in cases of schizophrenia, although many of these studies had technically incomplete characterization of this region 19 . We therefore expected to find examples of 22q11.2 deletions in our sample of 6,572 individuals. The most common form of 22q11.2DS is a 3-Mb loss (about 90% frequency), although a nested 1.5-Mb deletion is also observed (about 7%) along with infrequent (about 3%) atypical deletions 20 . We identified 13 large deletions (more than 500 kb) in cases of schizophrenia within this interval, and none in controls (Supplementary Table 7 ). Of these, six were consistent with the larger deletion, five were consistent with the shorter deletion, and two were atypical. The 11 samples with typical deletions defined an interval with the strongest association (empirical P 5 0.0017; genome-wide corrected P 5 0.0046; odds ratio 5 21.6) (Fig. 1a) . Controlling for sample collection site or genotyping plate instead of array type did not change the results (Supplementary Table 10 ). The two other atypical deletions in this region overlap the distal end of the 3-Mb variant. Deletion events within the region were confirmed in all 13 patients by quantitative polymerase chain reaction (qPCR) with three individual assays (Supplementary Fig. 1 and Supplementary Tables 11 and 12 ). Our findings provide additional evidence that hemizygosity in 22q11.2 is a rare but powerful risk factor for schizophrenia.
The larger 22q11.2 deletion harbours 43 genes (Supplementary Table 8 ). Despite the efforts of many groups, the psychiatric symptoms observed in 22q11.2DS have not been ascribed to a reduced copy number of any individual gene 12 . Variants within COMT, which encodes catechol-O-methyltransferase, an enzyme responsible for degrading catecholamines, including dopamine, have been implicated in a wide variety of phenotypes, but with inconsistent results 12 . Removing the thirteen 22q11.2DS individuals, we observed a further 271 deletions of more than 500 kb (161 in cases and 110 in controls). Two additional regions (15q13.3 and 1q21.1) were identified that harboured a significant excess of deletions in cases of schizophrenia after correction for multiple testing (Fig. 1b, c ; see Supplementary  Table 7 for case descriptions). On chromosome 15 (28-31 Mb) there were deletions in nine cases and no controls (empirical P 5 0.0029; genome-wide corrected P 5 0.046; odds ratio 17.9). On chromosome 1 (142.5-145.5 Mb) there were ten deletions in cases and one in controls (empirical P 5 0.0076; genome-wide corrected P 5 0.046; odds ratio 6.6). All 20 large deletions at 15q13.3 and 1q21.1 were validated by one or more qPCR reactions (Supplementary Fig. 1 and Supplementary Tables 11 and 12 ). The multiple test correction factors were small as a consequence of our having restricted attention to this small class of rare variants. We did not observe any regions with a corrected P , 0.05 for either duplications or smaller (less than 500 kb) deletions. In addition, the primary CNV burden tests remained significant after removing individuals with a deletion at one of these three loci (number P 5 10 24 and gene count P 5 3 3 10
25
); for deletions of more than 500 kb specifically, the burden test remained significant for number (P 5 0.02) but not for gene count (P 5 0.11).
The large deletions on chromosome 15q13.3 have not previously been associated with schizophrenia. This region does not include the nearby critical region for Prader-Willi/Angelman syndrome 21 but is consistent with the critical region defined by recurrent deletion in cases of mental retardation with seizures that have been reported recently 17 . Furthermore, our estimated breakpoints fall within the segmental duplications reported (BP4 and BP5). In the present study, evidence consistent with mildly impaired cognition was seen in five of the nine patients with deletions, and one individual also had a history of epilepsy (Supplementary Table 7 ). This broad region has been the focus of previous genetic studies in schizophrenia. The gene CHRNA7, encoding the a 7 subunit of the nicotinic acetylcholine receptor, is a candidate based on an initial identification from linkage analysis of auditory evoked potential deficits observed in patients with schizophrenia 22, 23 . The deleted region on 1q21.1 is consistent with a previously reported de novo deletion in a patient with learning disability and seizures 24 and two patients with autism (one de novo and one inherited) 10 . In the present study, three cases had mild cognitive abnormalities and one had a history of epilepsy (Supplementary Table 7 ). The region contains 27 known genes, most of which are expressed in the brain (Supplementary Table 8 ), and previous reports have shown linkage 25, 26 but there have been no previous reports of CNVs associated with schizophrenia.
Regions of highly homologous segmental duplication flank the deletions we report at 22q11.2, 15q13.3 and 1q21.1. A prominent mechanism for CNV genesis is non-allelic homologous recombination mediated by segmental duplications, resulting in deletions and reciprocal duplications of the interval between segmental duplications 16, 27 . Neurodevelopmental and psychiatric syndromes have been associated with deletions and duplications flanked by segmental duplications, many of which occur de novo 10, 11, 17 . . This indicates that at least some of these rare CNVs seen in cases but not in controls are probably risk factors for schizophrenia, although like Walsh et al. we are unable to identify which. Some examples of possible risk CNVs that were observed multiple times only in cases include deletions at 12p11.23 (four cases) and 16p12.2-12.1 (four cases). These deletions were more than 500 kb, flanked by segmental duplications and spanning several brain-expressed genes. In addition, duplications in two genes relevant to neural development and growth (NOTCH1 and p21-activated kinase 7, PAK7) were found in five and six cases, respectively, and no controls. Furthermore, we identified CNVs at two recently reported loci, NRXN1 and CNTNAP2 (refs 3, 5) (Supplementary Fig. 2 ).
The aetiology of schizophrenia has been vigorously debated. We now have strong and replicated 2 evidence that individuals with schizophrenia have a greater burden of structural variation across their genomes. Our data show that CNVs in at least three loci act as strong risk factors for schizophrenia in a minority of individuals. We can therefore now posit that some cases of schizophrenia are 'genomic disorders' 16 although we do not yet know whether the risk is specific for schizophrenia as opposed to a more general risk factor for neuropsychiatric or central nervous system illness.
Exactly how a subtle, 1.15-fold increase in CNV burden translates mechanistically into illness in a given patient is currently unknown. We also do not know whether common genetic variants of more subtle effect are components of the aetiology of schizophrenia, an empirical question that we and others are addressing. Similarly, we do not know how environmental risk or protective factors might act in concert with specific CNVs or with the overall burden of CNVs.
A critically important goal will be to determine the full clinical and phenotypic spectrum in carriers of these deletions. Our data provide preliminary evidence of a variable phenotype in patients with schizophrenia who would otherwise be regarded as clinically typical. Examining the role of these variants in related psychotic disorders, such as bipolar disorder, is imperative. Further work explicating the epidemiology and mechanism of these variants in schizophrenia may ultimately lead to a role for them in genetic counselling and understanding disease biology. Note added in proof: Samples from the University of Aberdeen were genotyped independently by the SGENE Consortium 30 .
METHODS SUMMARY
Cases satisfied DSM-IV 31 or ICD-10 (ref. 32) criteria for schizophrenia and were broadly representative of clinical cases in contact with psychiatric services. DNA was extracted from whole blood, with approval from institutional review boards. CNVs were identified with the Birdseye package 15 and analysed with PLINK v1.03 (ref. 14) . See Supplementary Information for details. A list of all CNVs passing quality control is available (http://pngu.mgh.harvard.edu/isc/).
